By Josh BeckermanShares of ResMed, a breathing technology company, fell after Eli Lilly said its weight-loss drug tirzepatide reduced the severity of sleep apnea in Phase 3 trials. Citi downgraded breathing technology company ResMed to neutral from buy on Monday. "Given the relatively modest near-term headwind we expect through FY27, we view today's weakness as a buying opportunity" for ResMed shares. Meanwhile, shares of Inspire Medical Systems, which provides technology for sleep apnea, were down 15% to $138.17. Write to Josh Beckerman at josh.beckerman@wsj.com(END) Dow Jones NewswiresJune 24, 2024 13:43 ET (17:43 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal June 24, 2024 23:49 UTC